Huei-Ju Ting, Ph.D.
Affiliations: | 2002 | University of Rochester, Rochester, NY |
Area:
Molecular Biology, OncologyGoogle:
"Huei-Ju Ting"Mean distance: 10177.7
Parents
Sign in to add mentor| Chawnshang Chang | grad student | 2002 | Rochester | |
| (The cloning and characterization of androgen receptor coregulators, supervillin and gelsolin.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hu YC, Yeh S, Yeh SD, et al. (2020) Correction: Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. The Journal of Biological Chemistry. 295: 17382 |
| Hu YC, Yeh S, Yeh SD, et al. (2020) Correction: Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. The Journal of Biological Chemistry. 295: 17382 |
| Altuwaijri S, Lee DK, Chuang KH, et al. (2020) Correction to: Androgen receptor regulates expression of skeletal muscle-specific proteins and muscle cell types. Endocrine |
| Lai GR, Lee YF, Yan SJ, et al. (2020) Active vitamin D induced gene-specific hypomethylation in prostate cancer cells developing vitamin D resistance. American Journal of Physiology. Cell Physiology |
| Lin VC, Huang SP, Ting HJ, et al. (2017) Vitamin D receptor-binding site variants affect prostate cancer progression. Oncotarget. 8: 74119-74128 |
| Hsu CL, Liu JS, Lin TW, et al. (2017) Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Oncotarget. 8: 69508-69519 |
| Lin VC, Huang SP, Ting HJ, et al. (2017) Vitamin D receptor-binding site variants affect prostate cancer progression. Oncotarget |
| Hsu CL, Liu JS, Lin TW, et al. (2017) Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Oncotarget |
| Hsu CL, Liu JS, Wu PL, et al. (2014) Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis. Molecular Oncology. 8: 1575-87 |
| Beckham CJ, Olsen J, Yin PN, et al. (2014) Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. The Journal of Urology. 192: 583-92 |